On offer is a participating interest in a leading Dutch bioinformatics company, which is on its way to world market leadership in its field. The company already has a virtually unmatchable lead on the competition, if any. The company has spent 14 years building up a database of specific biological molecule families and has built a platform and analysis software that not only allows the manipulation of the molecules concerned, but also predicts the effects of their mutations. This speeds up research time for protein engineering, medicines design and development, and DNA diagnostics. Licenses are sold on the data to renewed pharmaceutical, biotech and chemical technology companies and, in cooperation with partners, biotech projects are carried out, aimed at medicines development and sustainability projects, among others. Virtually all large pharmaceutical companies are customers.

Particularities
Turnover fluctuates quite a bit (between €1.5 m and €2 m), as the company is too small to make big steps forward. Over the years, there has been strong technical development, the company has also been able to retain highly qualified people, has invested heavily in technology (e.g. in server capacity), but continues to struggle with fluctuating sales at this stage. For that reason, it is looking for an early-stage investor who understands this business and sees the enormous global potential of what this company has to offer.

Transaction
The owner is searching for a professional (biotech or financial) investor, who together with the current management wants to shape and implement the growth strategy for the coming years, including setting up an in-house marketing & sales organisation. To this end, the owner offers a substantial interest in a pre-exit transaction.